GRÜNENTHAL STRENGTHENS ITS GENETIC MEDICINE CAPABILITIES AND JOINS THE CLUSTER FOR NUCLEIC ACID THERAPEUTICS MUNICH

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Joint venture

More Like This

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

GRÜNENTHAL'S PROPRIETARY NAV 1.8 INHIBITOR ENTERS CLINICAL DEVELOPMENT

SK pharmteco and Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy Program

PR Newswire associated0

Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics

PR Newswire associated0

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding

PR Newswire associated0

Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT